{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:08:11Z","timestamp":1790611691544,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) is characterized by immune system dysregulation after exposure to adjuvants, such as aluminum. Although cases of autoimmune thyroid diseases caused by ASIA have been reported, Graves' disease is one of the rarer diseases. There are some reports that vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause ASIA. Here, we describe a case of Graves\u2019 disease following SARS-CoV-2 vaccination and a review of the literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 41-year-old woman was admitted to our hospital because of palpitations and fatigue. Two weeks after receiving the second SARS-CoV-2 vaccine (BNT162b2, Coronavirus Modified Uridine messenger RNA (mRNA) Vaccine, Pfizer), she developed fatigue and gradually worsened. On admission, she exhibited thyrotoxicosis (thyroid-stimulating hormone (TSH)\u2009&lt;\u20090.01 mIU\/L (0.08\u20130.54), free triiodothyronine (FT3) 33.2\u00a0pmol\/L (3.8\u20136.3), and free thyroxine (FT4) 72.1\u00a0pmol\/L (11.6\u201319.3)) and palpitations associated with atrial fibrillation. TSH receptor antibody (TRAb) was positive (TRAb 5.0\u00a0IU\/L (&lt;\u20092.0)), and <jats:sup>99m<\/jats:sup>Tc scintigraphy showed diffuse uptake in the thyroid gland, suggesting that the thyrotoxicosis in this case was caused by Graves\u2019 disease. Thiamazole was prescribed to correct her condition, and soon after this treatment was initiated, her symptoms and thyroid hormone levels were significantly reduced.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case report reinforces the potential correlation between ASIA affecting the thyroid and SARS-CoV-2 mRNA vaccines. The clinical course suggests that it is essential to consider the possibility of developing ASIA, such as Graves' disease, after exposure to the SARS-CoV-2 vaccine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-023-01387-2","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T03:28:07Z","timestamp":1686799687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Graves\u2019 disease after exposure to the SARS-CoV-2 vaccine: a case report and review of the literature"],"prefix":"10.1186","volume":"23","author":[{"given":"Kai","family":"Takedani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-8154","authenticated-orcid":false,"given":"Masakazu","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Ishiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Asami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism Lancet. 2016;388:906\u201318.","journal-title":"Hyperthyroidism Lancet"},{"key":"1387_CR2","unstructured":"Subekti I, Pramono LA. Current Diagnosis and Management of Graves\u2019 Disease. Acta Med Indones. 2018;50:177\u201382."},{"key":"1387_CR3","doi-asserted-by":"publisher","first-page":"R241","DOI":"10.1530\/EJE-14-0047","volume":"170","author":"G Effraimidis","year":"2014","unstructured":"Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014;170:R241\u201352.","journal-title":"Eur J Endocrinol"},{"key":"1387_CR4","doi-asserted-by":"crossref","unstructured":"Shoenfeld Y, Agmon-Levin N. \u201cASIA\u201d - autoimmune\/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4\u20138.","DOI":"10.1016\/j.jaut.2010.07.003"},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2019.03.007","volume":"203","author":"A Watad","year":"2019","unstructured":"Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune\/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol. 2019;203:1\u20138.","journal-title":"Clin Immunol"},{"key":"1387_CR6","first-page":"150","volume":"7","author":"A Watad","year":"2016","unstructured":"Watad A, David P, Brown S, Shoenfeld Y. Autoimmune\/Inflammatory Syndrome Induced by Adjuvants and Thyroid Autoimmunity. Front Endocrinol (Lausanne). 2016;7:150.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5935\/1984-0063.20180008","volume":"11","author":"S Leiva","year":"2018","unstructured":"Leiva S, Madrazo J, Podesta C. Narcolepsy with cataplexy and hyperthyroidism sudden appeared after H1N1 vaccination. Sleep Sci. 2018;11:34\u20136.","journal-title":"Sleep Sci"},{"key":"1387_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101412","volume":"34","author":"NL Bragazzi","year":"2020","unstructured":"Bragazzi NL, Hejly A, Watad A, Adawi M, Amital H, Shoenfeld Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab. 2020;34: 101412.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1387_CR9","unstructured":"COVID19 VACCINE TRACKER. https:\/\/covid19.trackvaccines.org\/agency\/who\/. Accessed 5 March 2023."},{"key":"1387_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107970","volume":"99","author":"Y Ishay","year":"2021","unstructured":"Ishay Y, Kenig A, Tsemach-Toren T, Amer R, Rubin L, Hershkovitz YI, et al. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021;99: 107970.","journal-title":"Int Immunopharmacol"},{"key":"1387_CR11","doi-asserted-by":"crossref","unstructured":"Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, Medina G, S\u00e1nchez Valadez TI, Jara LJ. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune\/Inflammatory Syndrome Induced by Adjuvants. Thyroid. 2021.","DOI":"10.1089\/thy.2021.0142"},{"key":"1387_CR12","doi-asserted-by":"crossref","unstructured":"Duntas LH, Jonklaas J. COVID-19 and Thyroid Diseases: A Bidirectional Impact. J Endocr Soc. 2021;5:bvab076.","DOI":"10.1210\/jendso\/bvab076"},{"key":"1387_CR13","doi-asserted-by":"crossref","unstructured":"Murugan AK, Alzahrani AS. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves\u2019 disease. Endocrine. 2021;73:243\u201354.","DOI":"10.1007\/s12020-021-02770-6"},{"key":"1387_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271\u201380.","journal-title":"Cell"},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40249-020-00662-x","volume":"9","author":"MY Li","year":"2020","unstructured":"Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9:45.","journal-title":"Infect Dis Poverty"},{"key":"1387_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.26132","volume":"96","author":"EJ Lee","year":"2021","unstructured":"Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96:534\u20137.","journal-title":"Am J Hematol"},{"key":"1387_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102710","volume":"123","author":"\u00c9 Vuille-Lessard","year":"2021","unstructured":"Vuille-Lessard \u00c9, Montani M, Bosch J, Semmo N. Autoimmune hepatitis triggered by SARS-CoV-2 vaccination. J Autoimmun. 2021;123: 102710.","journal-title":"J Autoimmun"},{"key":"1387_CR18","doi-asserted-by":"crossref","unstructured":"Lui DTW, Lee KK, Lee CH, Lee ACH, Hung IFN, Tan KCB. Development of Graves\u2019 Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review. Front Public Health. 2021;9: 778964.","DOI":"10.3389\/fpubh.2021.778964"},{"key":"1387_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102738","volume":"125","author":"A Patrizio","year":"2021","unstructured":"Patrizio A, Ferrari SM, Antonelli A, Fallahi P. A case of Graves\u2019 disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J Autoimmun. 2021;125: 102738.","journal-title":"J Autoimmun"},{"key":"1387_CR20","doi-asserted-by":"crossref","first-page":"232470962110633","DOI":"10.1177\/23247096211063356","volume":"9","author":"MA Weintraub","year":"2021","unstructured":"Weintraub MA, Ameer B, Sinha GN. Graves Disease Following the SARS-CoV-2 Vaccine: Case Series. J Investig Med High Impact Case Rep. 2021;9:23247096211063356.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"1387_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246432","volume":"14","author":"TJ Goblirsch","year":"2021","unstructured":"Goblirsch TJ, Paulson AE, Tashko G, Mekonnen AJ. Graves\u2019 disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep. 2021;14: e246432.","journal-title":"BMJ Case Rep"},{"key":"1387_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/vaccines9101108","volume":"9","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Mashiba T, Takano K, Suzuki T, Kami M, Takita M, et al. A Case of Exacerbation of Subclinical Hyperthyroidism after First Administration of BNT162b2 mRNA COVID-19 Vaccine. Vaccines (Basel). 2021;9:1108.","journal-title":"Vaccines (Basel)"},{"key":"1387_CR23","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40618-021-01707-0","volume":"45","author":"A Pujol","year":"2022","unstructured":"Pujol A, G\u00f3mez LA, Gallegos C, Nicolau J, Sanch\u00eds P, Gonz\u00e1lez-Freire M, et al. Thyroid as a target of adjuvant autoimmunity\/infammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves\u2019 disease to silent thyroiditis. Endocrinol Invest. 2022;45:875\u201382.","journal-title":"Endocrinol Invest"},{"key":"1387_CR24","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0049","volume":"11","author":"R Manta","year":"2022","unstructured":"Manta R, Martin C, Muls V, Poppe KG. New-onset Graves\u2019 disease following SARS-CoV-2 vaccination: a case report. Eur Thyroid J. 2022;11: e220049.","journal-title":"Eur Thyroid J"},{"key":"1387_CR25","doi-asserted-by":"crossref","unstructured":"Zettinig G, Krebs M. Two further cases of Graves' disease following SARS-Cov-2 vaccination. J Endocrinol Invest. 2021:1\u20132.","DOI":"10.1007\/s40618-021-01650-0"},{"key":"1387_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2169\/internalmedicine.9231-21","volume":"61","author":"M Sakai","year":"2022","unstructured":"Sakai M, Takao K, Kato T, Ito K, Kubota S, Hirose T, et al. Graves\u2019 Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient. Intern Med. 2022;61:1561\u20135.","journal-title":"Intern Med"},{"key":"1387_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102809","volume":"128","author":"H Bostan","year":"2022","unstructured":"Bostan H, Ucan B, Kizilgul M, Calapkulu M, Hepsen S, Gul U, et al. Relapsed and newly diagnosed Graves\u2019 disease due to immunization against COVID-19: A case series and review of the literature. J Autoimmun. 2022;128: 102809.","journal-title":"J Autoimmun"},{"key":"1387_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40618-022-01739-0","volume":"45","author":"B PlaPeris","year":"2022","unstructured":"PlaPeris B, Merchante Alfaro A\u00c1, MaravallRoyo FJ, Abell\u00e1nGaliana P, P\u00e9rez Naranjo S, Gonz\u00e1lez BM. Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion. J Endocrinol Invest. 2022;45:1071\u20137.","journal-title":"J Endocrinol Invest"},{"key":"1387_CR29","first-page":"2627","volume":"26","author":"A Taieb","year":"2022","unstructured":"Taieb A, Sawsen N, Asma BA, Ghada S, Hamza E, Yosra H, et al. A rare case of grave\u2019s disease after SARS-CoV-2 vaccine: is it an adjuvant effect? Eur Rev Med Pharmacol Sci. 2022;26:2627\u201330.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1387_CR30","volume":"23","author":"W Hamouche","year":"2022","unstructured":"Hamouche W, El Soufi Y, Alzaraq S, Okafor BV, Zhang F, Paras C. A case report of new onset graves\u2019 disease induced by SARS-CoV-2 infection or vaccine? J Clin Transl Endocrinol Case Rep. 2022;23: 100104.","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.47102\/annals-acadmedsg.2021398","volume":"51","author":"MWJ Chua","year":"2022","unstructured":"Chua MWJ. Graves\u2019 disease after COVID-19 vaccination. Ann Acad Med Singap. 2022;51:127\u20138.","journal-title":"Ann Acad Med Singap"},{"key":"1387_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ando.2022.04.014","volume":"83","author":"F Br\u00e8s","year":"2022","unstructured":"Br\u00e8s F, Joyeux MA, Delemer B, Vitellius G, Barraud S. Three cases of thyroiditis after COVID-19 RNA-vaccine. Ann Endocrinol (Paris). 2022;83:262\u20134.","journal-title":"Ann Endocrinol (Paris)"},{"key":"1387_CR33","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s40618-022-01863-x","volume":"45","author":"RM Ruggeri","year":"2022","unstructured":"Ruggeri RM, Giovanellla L, Campenn\u00ec A. SARS-CoV-2 vaccine may trigger thyroid autoimmunity: real-life experience and review of the literature. J Endocrinol Invest. 2022;45:2283\u20139.","journal-title":"J Endocrinol Invest"},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"11492","DOI":"10.3390\/ijms231911492","volume":"23","author":"G Lioulios","year":"2022","unstructured":"Lioulios G, Tsouchnikas I, Dimitriadis C, Giamalis P, Pella E, Christodoulou M, et al. Two Cases of Autoimmune Thyroid Disorders after COVID Vaccination in Dialysis Patients. Int J Mol Sci. 2022;23:11492.","journal-title":"Int J Mol Sci"},{"key":"1387_CR35","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1210\/clinem\/dgac049","volume":"107","author":"SH O\u011fuz","year":"2022","unstructured":"O\u011fuz SH, \u015eendur SN, \u0130remli BG, G\u00fcrlek A, Erbas T, \u00dcnl\u00fct\u00fcrk U. SARS-CoV-2 Vaccine-induced Thyroiditis: Safety of Revaccinations and Clinical Follow-up. J Clin Endocrinol Metab. 2022;107:e1823\u201334.","journal-title":"J Clin Endocrinol Metab"},{"key":"1387_CR36","doi-asserted-by":"crossref","unstructured":"Pierman G, Delgrange E, Jonas C. Recurrence of Graves\u2019 Disease (a Th1-type Cytokine Disease) Following SARS-CoV-2 mRNA Vaccine Administration: A Simple Coincidence? Eur J Case Rep Intern Med. 2021;8: 002807.","DOI":"10.12890\/2021_002807"},{"key":"1387_CR37","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.jfma.2022.02.010","volume":"121","author":"SR Shih","year":"2022","unstructured":"Shih SR, Wang CY. SARS-CoV-2 vaccination related hyperthyroidism of Graves\u2019 disease. J Formos Med Assoc. 2022;121:1881\u20132.","journal-title":"J Formos Med Assoc"},{"key":"1387_CR38","doi-asserted-by":"crossref","unstructured":"Singh G, Howland T. Graves\u2019 Disease Following COVID-19 Vaccination. Cureus. 2022;14: e24418.","DOI":"10.7759\/cureus.24418"},{"key":"1387_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12902-023-01287-5","volume":"23","author":"S Yasuda","year":"2023","unstructured":"Yasuda S, Suzuki S, Yanagisawa S, Morita H, Haisa A, Satomura A, et al. HLA typing of patients who developed subacute thyroiditis and Graves\u2019 disease after SARS-CoV-2 vaccination: a case report. BMC Endocr Disord. 2023;23:54.","journal-title":"BMC Endocr Disord"},{"key":"1387_CR40","doi-asserted-by":"publisher","first-page":"e2324","DOI":"10.1210\/clinem\/dgac119","volume":"107","author":"YJ Chee","year":"2022","unstructured":"Chee YJ, Liew H, Hoi WH, Lee Y, Lim B, Chin HX, et al. SARS-CoV-2 mRNA Vaccination and Graves\u2019 Disease: A Report of 12 Cases and Review of the Literature. J Clin Endocrinol Metab. 2022;107:e2324\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"1387_CR41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12020-021-02902-y","volume":"74","author":"C Sriphrapradang","year":"2021","unstructured":"Sriphrapradang C, Shantavasinkul PC. Graves\u2019 disease following SARS-CoV-2 vaccination. Endocrine. 2021;74:473\u20134.","journal-title":"Endocrine"},{"key":"1387_CR42","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1507\/endocrj.EJ22-0208","volume":"69","author":"S Chaudhary","year":"2022","unstructured":"Chaudhary S, Dogra V, Walia R. Four cases of Graves\u2019 disease following viral vector severe acute respiratory syndrome corona virus-2 (SARSCoV-2) vaccine. Endocr J. 2022;69:1431\u20135.","journal-title":"Endocr J"},{"key":"1387_CR43","volume":"9","author":"D Cuenca","year":"2022","unstructured":"Cuenca D, Aguilar-Soto M, Mercado M. A Case of Graves\u2019 Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature. Eur J Case Rep Intern Med. 2022;9: 003275.","journal-title":"Eur J Case Rep Intern Med"},{"key":"1387_CR44","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.12998\/wjcc.v11.i5.1122","volume":"11","author":"BC Yan","year":"2023","unstructured":"Yan BC, Luo RR. Thyrotoxicosis in patients with a history of Graves\u2019 disease after SARS-CoV-2 vaccination (adenovirus vector vaccine): Two case reports. World J Clin Cases. 2023;11:1122\u20138.","journal-title":"World J Clin Cases"},{"key":"1387_CR45","doi-asserted-by":"crossref","unstructured":"Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol. 2020;15:963.","DOI":"10.1038\/s41565-020-00820-0"},{"key":"1387_CR46","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/j.bja.2020.12.020","volume":"126","author":"LH Garvey","year":"2021","unstructured":"Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126:e106\u20138.","journal-title":"Br J Anaesth"},{"key":"1387_CR47","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/all.14774","volume":"76","author":"SD Borgsteede","year":"2021","unstructured":"Borgsteede SD, Geersing TH, Tempels-Pavlica \u017d. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76:1941\u20132.","journal-title":"Allergy"},{"key":"1387_CR48","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/vaccines10091445","volume":"10","author":"A Patrizio","year":"2022","unstructured":"Patrizio A, Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, et al. Graves\u2019 Disease Following SARS-CoV-2 Vaccination: A Systematic Review. Vaccines (Basel). 2022;10:1445.","journal-title":"Vaccines (Basel)"},{"key":"1387_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617089","volume":"11","author":"A Vojdani","year":"2021","unstructured":"Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021;11: 617089.","journal-title":"Front Immunol"},{"key":"1387_CR50","doi-asserted-by":"crossref","unstructured":"Triantafyllidis KK, Giannos P, Stathi D, Kechagias KS. Graves\u2019 disease following vaccination against SARS-CoV-2: A systematic review of the reported cases. Front Endocrinol (Lausanne). 2022;13: 938001.","DOI":"10.3389\/fendo.2022.938001"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01387-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T03:28:16Z","timestamp":1686799696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01387-2","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}